New phosphatidylinositol 3-kinase inhibitors for cancer

Bibliography

• Sugimoto Y, Whitman M, Cantley LC, Erikson RL. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci USA 1984;81(7):2117-21
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7(8):606-19
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27(41):5497-510
   PubMed Web of Science ®Google Scholar
• Katso R, Okkenhaug K, Ahmadi K, Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-75
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304(5670):554
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2(2):127-37
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Liu Z, Wang L, The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 2005;102(51):18443-8
   PubMed Web of Science ®Google Scholar
• Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28(34):3009-21
   PubMed Web of Science ®Google Scholar
• Carpenter CL, Auger KR, Chanudhuri M, Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem 1993;268(13):9478-83
   PubMed Web of Science ®Google Scholar
• Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27(41):5486-96
   PubMed Web of Science ®Google Scholar
• Alessi DR, Deak M, Casamayor A, 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 1997;7(10):776-89
   PubMed Web of Science ®Google Scholar
• Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9(1):59-71
   PubMed Web of Science ®Google Scholar
• Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010;16(1):34-44
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441(7092):424-30
   PubMed Web of Science ®Google Scholar
• Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273(22):13375-8
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275(5308):1943-7
   PubMed Web of Science ®Google Scholar
• Cho H, Mu J, Kim JK, Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001;292(5522):1728-31
   PubMed Web of Science ®Google Scholar
• Taniguchi CM, Tran TT, Kondo T, Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci USA 2006;103(32):12093-7
   PubMed Web of Science ®Google Scholar
• Luo J, Sobkiw CL, Hirshman MF, Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab 2006;3(5):355-66
   PubMed Web of Science ®Google Scholar
• Knight ZA, Gonzalez B, Feldman ME, A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006;125(4):733-47
   PubMed Web of Science ®Google Scholar
• Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010;7(4):209-19
   PubMed Web of Science ®Google Scholar
• Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010;19(11):1355-66
   PubMed Web of Science ®Google Scholar
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321(5897):1807-12
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12(4):395-402
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Martini M, Molinari F, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69(5):1851-7
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11(8):753-62
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Guo H, Zhang S, PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010;177(4):1647-56
   PubMed Web of Science ®Google Scholar
• Ma YY, Wei SJ, Lin YC, PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19(23):2739-44
   PubMed Web of Science ®Google Scholar
• Woenckhaus J, Steger K, Werner E, Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 2002;198(3):335-42
   PubMed Web of Science ®Google Scholar
• Pedrero JM, Carracedo DG, Pinto CM, Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114(2):242-8
   PubMed Web of Science ®Google Scholar
• Massion PP, Kuo WL, Stokoe D, Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002;62(13):3636-40
   PubMed Web of Science ®Google Scholar
• Kawano O, Sasaki H, Okuda K, PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 2007;58(1):159-60
   PubMed Web of Science ®Google Scholar
• Byun DS, Cho K, Ryu BK, Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003;104(3):318-27
   PubMed Web of Science ®Google Scholar
• Nakayama K, Nakayama N, Kurman RJ, Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 2006;5(7):779-85
   PubMed Web of Science ®Google Scholar
• Nakayama K, Nakayama N, Jinawath N, Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007;120(12):2613-17
   PubMed Web of Science ®Google Scholar
• Wu G, Mambo E, Guo Z, Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 2005;90(8):4688-93
   PubMed Web of Science ®Google Scholar
• Miller CT, Moy JR, Lin L, Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res 2003;9(13):4819-25
   PubMed Web of Science ®Google Scholar
• Kita D, Yonekawa Y, Weller M, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 2007;113(3):295-302
   PubMed Web of Science ®Google Scholar
• Kolasa IK, Rembiszewska A, Felisiak A, PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 2009;8(1):21-6
   PubMed Web of Science ®Google Scholar
• Park SW, Kang MR, Eom HS, Somatic mutation of PIK3R1 gene is rare in common human cancers. Acta Oncol 2010;49(1):125-7
   PubMed Web of Science ®Google Scholar
• Philp AJ, Campbell IG, Leet C, The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61(20):7426-9
   PubMed Web of Science ®Google Scholar
• Mizoguchi M, Nutt CL, Mohapatra G, Louis DN. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol 2004;14(4):372-7
   PubMed Web of Science ®Google Scholar
• Jaiswal BS, Janakiraman V, Kljavin NM, Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 2009;16(6):463-74
   PubMed Web of Science ®Google Scholar
• Li L, Plummer SJ, Thompson CL, Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res 2008;14(3):633-7
   PubMed Web of Science ®Google Scholar
• Chen M, Gu J, Delclos GL, Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 2010;31(8):1387-91
   PubMed Web of Science ®Google Scholar
• Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007;12(2):104-7
   PubMed Web of Science ®Google Scholar
• Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 2000;19(44):5083-90
   PubMed Web of Science ®Google Scholar
• Jia S, Liu Z, Zhang S, Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008;454(7205):776-9
   PubMed Web of Science ®Google Scholar
• Wee S, Wiederschain D, Maira SM, PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 2008;105(35):13057-62
   PubMed Web of Science ®Google Scholar
• Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2006;103(5):1289-94
   PubMed Web of Science ®Google Scholar
• Sujobert P, Bardet V, Cornillet-Lefebvre P, Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005;106(3):1063-6
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010;116(9):1460-8
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, CAL-101, a p110{delta} selective phosphatidylinositol-3-kinase inhibitor (PI3K) for the treatment of B cell malignancies inhibits PI3K signaling and cellular viability. Blood 2011;117(2):591-4
   Google Scholar
• Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000;37(11):828-30
   PubMed Web of Science ®Google Scholar
• Garcia JM, Silva J, Pena C, Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004;41(2):117-24
   PubMed Web of Science ®Google Scholar
• Goel A, Arnold CN, Niedzwiecki D, Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004;64(9):3014-21
   PubMed Web of Science ®Google Scholar
• Escriva M, Peiro S, Herranz N, Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol 2008;28(5):1528-40
   PubMed Web of Science ®Google Scholar
• Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133(3):403-14
   PubMed Web of Science ®Google Scholar
• Freihoff D, Kempe A, Beste B, Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 1999;79(5-6):754-8
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Oki E, Kimura Y, Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat 2007;101(3):249-57
   PubMed Web of Science ®Google Scholar
• Oki E, Kakeji Y, Baba H, Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer. J Gastroenterol Hepatol 2006;21(5):814-18
   PubMed Web of Science ®Google Scholar
• Birck A, Ahrenkiel V, Zeuthen J, Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 2000;114(2):277-80
   PubMed Web of Science ®Google Scholar
• Pollock PM, Walker GJ, Glendening JM, PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res 2002;12(6):565-75
   PubMed Web of Science ®Google Scholar
• Pesche S, Latil A, Muzeau F, PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998;16(22):2879-83
   PubMed Web of Science ®Google Scholar
• Ollikainen M, Gylling A, Puputti M, Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 2007;121(4):915-20
   PubMed Web of Science ®Google Scholar
• Sos ML, Koker M, Weir BA, PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69(8):3256-61
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28(6):1075-83
   PubMed Web of Science ®Google Scholar
• Guix M, Faber AC, Wang SE, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008;118(7):2609-19
   Google Scholar
• Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62(1):200-7
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Iida M, Kruser TJ, Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009;8(8):696-703
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29(34):4741-51
   PubMed Web of Science ®Google Scholar
• Frederick BA, Helfrich BA, Coldren CD, Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007;6(6):1683-91
   PubMed Web of Science ®Google Scholar
• Fu J, Chen Y, Cao J, p28(GANK) overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 2011;53(1):181-92
   PubMed Web of Science ®Google Scholar
• Wang SE, Xiang B, Guix M, Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 2008;28(18):5605-20
   PubMed Web of Science ®Google Scholar
• Song LB, Li J, Liao WT, The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009;119(12):3626-36
   PubMed Web of Science ®Google Scholar
• Zhu QS, Rosenblatt K, Huang KL, Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 2011;30(4):457-70
   Google Scholar
• Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br J Cancer 2010;103(4):439-45
   PubMed Web of Science ®Google Scholar
• Dubrovska A, Kim S, Salamone RJ, The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009;106(1):268-73
   PubMed Web of Science ®Google Scholar
• Soeda A, Park M, Lee D, Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009;28(45):3949-59
   PubMed Web of Science ®Google Scholar
• Dubrovska A, Elliott J, Salamone RJ, Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin Cancer Res 2010;16(23):5692-702
   PubMed Web of Science ®Google Scholar
• Sunayama J, Sato A, Matsuda K, Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 2010;12(12):1205-19
   PubMed Web of Science ®Google Scholar
• Liu Y, Shreder KR, Gai W, Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol 2005;12(1):99-107
   PubMed Web of Science ®Google Scholar
• Liu Y, Jiang N, Wu J, Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem 2007;282(4):2505-11
   PubMed Web of Science ®Google Scholar
• Schultz RM, Merriman RL, Andis SL, In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995;15(4):1135-9
   PubMed Web of Science ®Google Scholar
• Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001;7(10):3269-75
   PubMed Web of Science ®Google Scholar
• Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269(7):5241-8
   PubMed Web of Science ®Google Scholar
• Knight ZA, Shokat KM. Chemically targeting the PI3K family. Biochem Soc Trans 2007;35(Pt 2):245-9
   PubMed Web of Science ®Google Scholar
• Ihle NT, Williams R, Chow S, Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3(7):763-72
   PubMed Web of Science ®Google Scholar
• Howes AL, Chiang GG, Lang ES, The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 2007;6(9):2505-14
   PubMed Web of Science ®Google Scholar
• Ihle NT, Paine-Murrieta G, Berggren MI, The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005;4(9):1349-57
   PubMed Web of Science ®Google Scholar
• Ihle NT, Lemos R Jr, Wipf P, Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009;69(1):143-50
   PubMed Web of Science ®Google Scholar
• Jimeno A, Herbst RS, Falchook GS, Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. J Clin Oncol 2010;28(15s): abstract 3089
   Google Scholar
• Edelman G, Bedell C, Shapiro GI, A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010;28(15s): abstract 3004
   PubMed Web of Science ®Google Scholar
• Traynor AM, Kurzrock R, Bailey HH, A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(15s): abstract 3078
   Google Scholar
• Moldovan C, Soria J, LoRusso P, A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(15s): abstract 3070
   Google Scholar
• Baselga J, De Jonge MJ, Rodon J, A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(15s): abstract 3003
   Google Scholar
• Folkes AJ, Ahmadi K, Alderton WK, The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51(18):5522-32
   PubMed Web of Science ®Google Scholar
• Floris G, Sciot R, Wozniak A, Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib. J Clin Oncol 2010;28(15s): abstract 10020
   Google Scholar
• Wagner AJ, Von Hoff DH, LoRusso PM, A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol 2009;27(15s): abstract 3501
   Google Scholar
• Herman SE, Gordon AL, Wagner AJ, Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116(12):2078-88
   PubMed Web of Science ®Google Scholar
• Furman RR, Byrd JC, Flinn IW, Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 2010;28(15s): abstract 3032
   Google Scholar
• Brana I, LoRusso P, Baselga J, A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010;28(15s): abstract 3030
   PubMed Web of Science ®Google Scholar
• Cohen RB, Janne PA, Engelman JA, A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(15s): abstract 3015
   Google Scholar
• Nghiemphu PL, Omuro AM, Cloughesy TF, A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. J Clin Oncol 2010;28(15s): abstract 3085
   Google Scholar
• Garlich JR, De P, Dey N, A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008;68(1):206-15
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Mahadevan D, Harris WB, Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol 2009;27(15s): abstract 2558
   Google Scholar
• Maira SM, Stauffer F, Brueggen J, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7(7):1851-63
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14(12):1351-6
   PubMed Web of Science ®Google Scholar
• Serra V, Markman B, Scaltriti M, NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68(19):8022-30
   PubMed Web of Science ®Google Scholar
• Crowder RJ, Phommaly C, Tao Y, PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009;69(9):3955-62
   PubMed Web of Science ®Google Scholar
• Burris H, Rodon J, Sharma S, First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(15s): abstract 3005
   Google Scholar
• Dolly S, Wagner AJ, Bendell JC, A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma. J Clin Oncol 2010;28(15s): abstract 3079
   Google Scholar
• Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9(8):643-60
   PubMed Web of Science ®Google Scholar
• Prasad A, Park IW, Allen H, Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 2009;28(12):1518-28
   PubMed Web of Science ®Google Scholar
• Janku F, Tsimberidou AM, Garrido-Laguna I, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitor. Mol Cancer Ther 2011 Jan 7. [Epub ahead of print]
   Google Scholar